To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Revolutionary technology will further boost OneSource’s scientific services offerings
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Shivani Satish Wagh takes on the role of Joint Managing Director
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options
Subscribe To Our Newsletter & Stay Updated
